Quantitation of herpes simplex DNA in blood during aciclovir therapy with competitive PCR ELISA.
Monitoring viral load in blood has already been introduced into clinical routine for human immunodeficiency virus and hepatitis C virus. This study was conducted to monitor the decline of herpes simplex (HSV) viral load in the blood of a patient with gingivostomatitis herpetica prior and during acyclovir therapy. Analysis was done by quantitative PCR ELISA using an internal quantitation standard. Copy numbers were 66/microl blood prior to therapy, 60 during oral medication with valaciclovir, 97 and 72 copies/microl blood during the first 2 days of intravenous acyclovir therapy, followed by a sharp decline to 8 and 9 copies on days 3 and 4. During the following days, HSV was no longer detectable. As this quantitative approach can be easily adjusted to any other PCR, it provides a reliable, easy-to-apply method for monitoring therapy, also during new antiviral clinical trials.